PWM
NEO icon

Parkworth Wealth Management’s NeoGenomics NEO Stock Holding History

Parkworth Wealth Management’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$16 – 1275
2024
Q4 		$16 Buy
+1
New +$16 ﹤0.01% 1252

Other funds holding NEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Parkworth Wealth Management's NEO Position: Q1 2025 in Review

Parkworth Wealth Management sold out of NeoGenomics (NEO) in Q1 2025, closing a stake of 1 share — an estimated $16 sold.

Parkworth Wealth Management first reported a position in NEO in Q4 2024 and held it in 1 quarter. The position peaked at $16 in Q4 2024. 256 funds tracked by Wall St. Rank hold NEO as of Q1 2025.

  • Parkworth Wealth Management reported no remaining NeoGenomics position as of Q1 2025 after selling out during the quarter.
  • Parkworth Wealth Management sold 1 NeoGenomics share in Q1 2025, an estimated $16.
  • Parkworth Wealth Management first reported a position in NeoGenomics in Q4 2024 and held it in 1 quarter.
  • Parkworth Wealth Management's NeoGenomics position peaked at $16 in Q4 2024.
  • 256 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2025.

Based on Parkworth Wealth Management's 13F filing for Q1 2025, filed 5 May 2025.